A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.

Autor: Latzer P; Zentrum für Humangenetik Tübingen, Tübingen, Germany., Zelba H; Zentrum für Humangenetik Tübingen, Tübingen, Germany., Battke F; CeGaT GmbH, Tübingen, Germany., Reinhardt A; Zentrum für Humangenetik Tübingen, Tübingen, Germany., Shao B; Zentrum für Humangenetik Tübingen, Tübingen, Germany., Bartsch O; Zentrum für Humangenetik Tübingen, Tübingen, Germany., Rabsteyn A; Zentrum für Humangenetik Tübingen, Tübingen, Germany., Harter J; CeGaT GmbH, Tübingen, Germany., Schulze M; Zentrum für Humangenetik Tübingen, Tübingen, Germany., Okech T; MVZ Zentrum für ambulante Onkologie GmbH, Tübingen, Germany., Golf A; MVZ Zentrum für ambulante Onkologie GmbH, Tübingen, Germany., Kyzirakos-Feger C; Zentrum für Humangenetik Tübingen, Tübingen, Germany., Kayser S; Zentrum für Humangenetik Tübingen, Tübingen, Germany., Pieper N; Zentrum für Humangenetik Tübingen, Tübingen, Germany., Feldhahn M; CeGaT GmbH, Tübingen, Germany., Wünsche J; Zentrum für Humangenetik Tübingen, Tübingen, Germany.; MVZ Zentrum für ambulante Onkologie GmbH, Tübingen, Germany., Seitz C; Universitätsklinikum Heidelberg, KiTZ, Hopp Children's Cancer Center, Heidelberg, Germany., Hadaschik D; CeCaVa GmbH, Tübingen, Germany., Garbe C; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany., Hauser TK; Department für Radiologie, Universitätsklinikum Tübingen, Tübingen, Germany., la Fougère C; Nuklearmedizin und Klinische Molekulare Bildgebung, Universitätsklinikum Tübingen, Tübingen, Germany., Biskup D; CeGaT GmbH, Tübingen, Germany., Brooke D; Provenance Precision Medicine Foundation, Wilmette, IL, USA., Parker D; PHM, Los Angeles, CA, USA., Martens UM; Department of Hematology and Oncology, Cancer Center Heilbronn-Franken, SLK Kliniken GmbH, Heilbronn, Germany., Illerhaus G; Klinikum Stuttgart, Stuttgart, Germany., Blumenthal DT; Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel Aviv, Israel., Merrell R; Vanderbilt University Medical Center, Nashville, TN, USA., Lorenzo LS; Clínica Universidad de Navarra, Madrid, Spain., Hidvégi M; Jewish Theological Seminary-University of Jewish Studies (OR-ZSE), Budapest, Hungary., de Robles P; Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.; Tom Baker Cancer Centre, Calgary, AB, Canada., Kebir S; Universitätsklinikum Essen, Essen, Germany., Li WW; Angiogenesis Foundation, Cambridge, MA, USA., Li VW; Angiogenesis Foundation, Cambridge, MA, USA.; Harvard Medical School Dermatology, Boston, MA, USA., Williams M; NHS London, London, UK., Miller AM; Brain and Spine Tumor Center, NYU Langone Health's Perlmutter Cancer Center, New York, NY, USA., Kesari S; Pacific Neuroscience Institute, Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA., Castro M; Cellworks Group Inc, South San Francisco, CA, USA.; Personalized Cancer Medicine, PLLC, Santa Monica, CA, USA., Desjardins A; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Ashley DM; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.; Preston Robert Tisch Brain Tumor Centre, Duke University, Durham, NC, USA., Friedman HS; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Neil EC; Department of Neurology, University of Minnesota Health, Minneapolis, MN, USA., Iwamoto FM; Columbia University Medical Center, New York, NY, USA., Sipos B; BAG für Pathologie und Molekularpathologie Stuttgart, Molekularpathologie Baden-Württemberg GbR, Stuttgart, Germany., Geletneky K; Klinikum Darmstadt GmbH, Darmstadt, Germany., Zender L; University Hospital Tübingen, Internal Medicine VIII, Tübingen, Germany., Glas M; Division of Clinical Neurooncology, Department of Neurology, Universitätsklinikum Essen Klinik für Neurologie, Essen, Germany., Reardon DA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Biskup S; Zentrum für Humangenetik Tübingen, Tübingen, Germany. Saskia.Biskup@humangenetik-tuebingen.de.; CeGaT GmbH, Tübingen, Germany. Saskia.Biskup@humangenetik-tuebingen.de.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2024 Aug 11; Vol. 15 (1), pp. 6870. Date of Electronic Publication: 2024 Aug 11.
DOI: 10.1038/s41467-024-51315-8
Abstrakt: Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens. All patients were treated within the scope of an individual healing attempt. Among all vaccinated patients, including 70 treated prior to progression (primary) and 103 treated after progression (recurrent), the median overall survival from first diagnosis is 31.9 months (95% CI: 25.0-36.5). Adverse events are infrequent and are predominantly grade 1 or 2. A vaccine-induced immune response to at least one of the vaccinated peptides is detected in blood samples of 87 of 97 (90%) monitored patients. Vaccine-specific T-cell responses are durable in most patients. Significantly prolonged survival is observed for patients with multiple vaccine-induced T-cell responses (53 months) compared to those with no/low induced responses (27 months; P = 0.03). Altogether, our results highlight that the application of personalized neoantigen-targeting peptide vaccine is feasible and represents a promising potential treatment option for GBM patients.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: